Aurinia Launches Its First Drug With Lupkynis Approval For Lupus Nephritis

The calcineurin inhibitor, only the second drug to be approved by the US FDA for lupus nephritis, will be competing against GlaxoSmithKline’s Benlysta.

Nature background concept: Alone tree on meadow sunset.
Aurinia is launching its first commercial drug and doing it independently • Source: Shutterstock

Aurinia Pharmaceuticals Inc. is going it alone on the US launch of Lupkynis (voclosporin) for lupus nephritis, marking the company's transition to a fully integrated biopharmaceutical company. But the small single-asset drug company will be going up against a much more experienced and deep-pocketed rival in the form of GlaxoSmithKline plc, which also recently received a LN indication for Benlysta.

Lupkynis, a calcineurin inhibitor (CNI), was approved by the US Food and Drug Administration on 22 January for the treatment...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Immunological

More from Therapeutic Category